Altered Urinary Porphyrin Excretion in a Human Po p ulation Chronically Exposed to Arsenic in Mexico
Por:
García-Vargas G.G., Del Razo L.M., Cebrián M.E., Albores A., Ostrosky-Wegman P., Montero R., Gonsebatt M.E., Lim C.K., de Matteis F.
Publicada:
1 ene 1994
Resumen:
1 A detailed study of the urinary excretion pattern of porphyrins in humans chronically exposed to As via drinking water was performed using high performance liquid chromatography (HPLC) 2 Thirty-six individuals (15 men and 21 women) were selected from a town which had 0.400 mg L-1 of As in drinking water. The control group consisted of thirty-one individuals (13 men and 18 women) whose As concentration in drinking water was 0.020 mg L-1 3 The major abnormalities in the urinary porphyrin excretion pattern observed in arsenic-exposed individuals were: (a) significant reductions in coproporphyrin III excretion resulting in decreases in the COPRO III/COPRO I ratio, and (b) significant increases in uroporphyrin excretion. Both alterations were responsible for the decrease in the COPRO/URO ratio. 4 No porphyrinogenic response was found in individuals with urinary As concentrations below 1,000 ?g of As g-1 of creatinine, However, as arsenic concentrations exceeded this value, the excretion of porphyrins (except coproporphyrin III) increased proportionally. 5 The prevalence of clinical signs of arsenicism showed a direct relationship to both As concentration in urine and time-weighted exposure to As. A direct relationship between time-weighted exposure and alterations in urinary porphyrin excretion ratios was also observed. 6 The alterations found are compatible with a lower uroporphyrinogen decarboxylase activity in arsenic-exposed individuals. However, the similarities in the urinary porphyrin excretion pattern between As-exposed individuals and Dubin-Johnson syndrome patients suggest that impairments in the excretion of coproporphyrin isomers may also contribute to the pattern observed. © 1994, Sage Publications. All rights reserved.
Filiaciones:
García-Vargas G.G.:
MRC Toxicology Unit, Hodkin Building, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK, United Kingdom
Del Razo L.M.:
Sección de Toxicologia Ambiental, Departamento de Farmacologia y Toxicologia, CINVESTAV-IPN, P.O. Box 14-740, DF 07000, México, United States
Cebrián M.E.:
Sección de Toxicologia Ambiental, Departamento de Farmacologia y Toxicologia, CINVESTAV-IPN, P.O. Box 14-740, DF 07000, México, United States
Albores A.:
Sección de Toxicologia Ambiental, Departamento de Farmacologia y Toxicologia, CINVESTAV-IPN, P.O. Box 14-740, DF 07000, México, United States
Ostrosky-Wegman P.:
Instituto de Investigaciones Biomédicas, UNAM, México, DF, México, United States
Montero R.:
Instituto de Investigaciones Biomédicas, UNAM, México, DF, México, United States
Gonsebatt M.E.:
Instituto de Investigaciones Biomédicas, UNAM, México, DF, México, United States
Lim C.K.:
MRC Toxicology Unit, Hodkin Building, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK, United Kingdom
de Matteis F.:
MRC Toxicology Unit, Hodkin Building, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK, United Kingdom
|